

POPULATION

N = 5,988  
HFpEF patients with EF  
>40%

INTERVENTION

Empagliflozin  
10mg daily

COMPARATOR

Placebo

PRIMARY ENDPOINT: CV death or HF hospitalization

**HR 0.79**

95% CI: 0.69-0.90

**p <0.001**

Safety Findings

Limitations

Clinical Implications: First therapy to show benefit in HFpEF